TSMHT
INSM icon

Thurston Springer Miller Herd & Titak’s Insmed INSM Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13K Hold
20
– – ﹤0.01% 1091
2026
Q1 		$3.27K Hold
20
– – ﹤0.01% 1115
2025
Q4 		$3.48K Buy
+20
New +$3.65K ﹤0.01% 1150

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's INSM Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Insmed (INSM) position steady in Q2 2026 at 20 shares worth $2.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Thurston Springer Miller Herd & Titak first reported a position in INSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.48K in Q4 2025. 665 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • Thurston Springer Miller Herd & Titak held 20 shares of Insmed worth $2.13K as of Q2 2026.
  • Thurston Springer Miller Herd & Titak left its Insmed share count unchanged in Q2 2026.
  • Insmed made up ﹤0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #1091 holding.
  • Thurston Springer Miller Herd & Titak first reported a position in Insmed in Q4 2025 and has held it in 3 quarters since.
  • Thurston Springer Miller Herd & Titak's Insmed position peaked at $3.48K in Q4 2025.
  • 665 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.